Medanta's Q4 Earnings Soar 42% Amid Expansion, Analyst Lifts Price Target

HEALTHCARE
Whalesbook Logo
AuthorKavya Nair|Published at:
Medanta's Q4 Earnings Soar 42% Amid Expansion, Analyst Lifts Price Target
Overview

Medanta, operated by Global Health, announced a robust Q4FY26 with revenue up 25%, EBITDA up 9%, and net profit surging 42% past estimates. While newer facilities had lower occupancy, overall margins improved. The company added 623 beds. Anand Rathi maintained a BUY rating, raising the price target to Rs1,400.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • Quarterly Results
  • Concall Announcements
  • New Orders & Big Deals
  • Capex Announcements
  • Bulk Deals
  • And much more

Global Health (Medanta) achieved strong financial results in Q4FY26, marked by a significant year-over-year increase in revenue, EBITDA, and net profit. The Average Revenue Per Occupied Bed (ARPOB) rose by 5%, reflecting improved pricing power and service value, supported by strategic capacity expansion.

Margins Improve Despite Lower Occupancy

While occupancy rates at facilities including Lucknow, Patna, and the new Noida unit were lower, averaging 44%, margins for these newer operations (excluding Noida) grew by 220 basis points year-over-year to 32.4%. This improvement in margins, even with reduced utilization, indicates effective cost management. Global Health added 623 beds during FY26 across Noida, Patna, and Ranchi, increasing its total capacity to 3,665 beds.

Analyst Reaffirms Buy Rating

Anand Rathi forecasts continued growth for Global Health, projecting compound annual growth rates of 15% for revenue, 24% for EBITDA, and 18% for net profit between FY26 and FY28. The brokerage firm reiterated its BUY rating and revised its price target to Rs1,400, based on 26 times FY28 estimated EV/EBITDA, showing confidence in the company's earnings potential and alignment with industry peers.

Potential Challenges Ahead

The lower occupancy rates (44%) at new facilities in Lucknow, Patna, and Noida represent a ramp-up period that could affect short-term profitability if patient flow doesn't meet expectations. Achieving projected occupancy and profitability targets will depend on consistent patient acquisition and managing competitive pressures. Anand Rathi's slight reduction in the price target to Rs1,400 from Rs1,450 may signal a careful adjustment to growth forecasts.

Positive Growth Outlook

Analysts anticipate sustained revenue and EBITDA growth for Global Health through FY28, driven by its ongoing capacity additions and margin improvement strategies. The favorable healthcare sector, boosted by increased spending and an aging population, supports Medanta's growth plans. The market will monitor the ramp-up of new facilities and their impact on overall occupancy and profitability.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.